| abstract |
The present invention provides a combination of selective dopamine D2 receptor antagonist and 5-HT1A receptor agonist compounds, in particular (R) - (-) - 2- [5- (4-fluorophenyl) -3-pyridylmethylaminomethyl] -chroman and physiologically acceptable salts thereof, and N - relates to the use of (4'-fluoro-3-biphenylmethyl) -N-2- (3-cyanophenoxyethyl) amine and its physiologically acceptable salts, in the manufacture of a medicament for use in veterinary medicine that is associated with behavioral stress in animals, and treating obsessive-compulsive disorders and / or anxiety disorders associated with behavioral stress sources. SHE |